


**Product Name** : CB-103  
**Cat. No.** : PC-38257  
**CAS No.** : 218457-67-1  
**Molecular Formula** : C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O  
**Molecular Weight** : 242.322  
**Target** : Notch  
**Solubility** : 100 mM in DMSO (24 mg/mL)



## Biological Activity

CB-103 (CB103) is an orally active small-molecule inhibitor of the **Notch** transcription activation complex, inhibits both ligand-dependent and ligand-independent Notch activation in cell-based assays (IC<sub>50</sub>=0.9-3.9 μM).

CB-103 does not inhibit Wnt or Hedgehog signaling using reporter assays.

CB-103 inhibits Notch signaling in primary human T cell acute lymphoblastic leukemia and other Notch-dependent human tumor cell lines, and concomitantly induces cell cycle arrest and apoptosis, thereby impairing proliferation, including in GSI-resistant human tumor cell lines with chromosomal translocations and rearrangements in Notch genes.

CB-103 produces Notch loss-of-function phenotypes in flies and mice. CB-103 inhibits the growth of human breast cancer and leukemia xenografts, notably without causing the dose-limiting intestinal toxicity associated with other Notch inhibitors.

## References

Lehal R, et al. *Proc Natl Acad Sci U S A*. 2020 Jul 14;117(28):16292-16301.

Lue JK, et al. *Ann Lymphoma*. 2020 Sep 30;4:7.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com